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more trouble?1 Vertex press release (24 June, 2014): “Two 24-week phase 3 studies of
lumacaftor in combination with ivacaftor met primary endpoint with statistically
signiﬁcant improvements in lung function (FEV1) in people with cystic ﬁbrosis
who have two copies of the F508del mutation” (http://investors.vrtx.com/
releasedetail.cfm?ReleaseID=856185).The discovery and rapid translation of the CFTR potentiator
ivacaftor (VX-770) from an in vitro investigational compound
to the first approved mutation-specific drug therapy tackling the
root cause of CF is an unprecedented success for the CF
community [1–4]. It argues persuasively that pharmacological
correction of CFTR mutants may be feasible on a broader scale,
giving hope that mutation-specific drug therapies may possibly
become available to all patients with CF. Currently, ivacaftor is
approved by the US Food and Drug Administration (FDA) and
the European Medicines Agency (EMA) for G551D-CFTR and
eight other mutations. Each of these mutations likely causes a
single defect in the CFTR gene, which disrupts CFTR function
as an epithelial chloride (Cl−) channel by impeding channel
opening. By contrast, many of the CF mutations that have been
studied to date impact channel number and function in multiple
ways (for review, see [5]); the same is anticipated to be the case
for the large majority of rare CF mutations yet to be investigated
in the laboratory. The spectrum of defects assailing CFTR is best
illustrated by F508del, the most common CF mutation. F508del
causes a temperature-sensitive folding defect that prevents CFTR
delivery to its correct cellular location, the apical membrane of
epithelia. Any F508del-CFTR protein that evades the sentinels
tasked to identify mutant proteins in the cell exhibits two further
defects: protein instability and defective channel regulation. At
the plasma membrane, F508del-CFTR has a fragile structure,
which rapidly falls apart. As for G551D-CFTR, it is also more
difficult to open the F508del-CFTR channel. However, the mo-
lecular basis of this defect is distinct from that of G551D-CFTR.
Thus, mutation-specific drug therapy for F508del-CFTR needs to
fix multiple problems.
Laboratory studies demonstrate that F508del-CFTR can be
transformed using one or more CFTR correctors (drugs designed
to promote normal protein folding) and a CFTR potentiator to
boost channel function [2]. Encouragingly, van Goor et al. [6]
demonstrated that the combination of lumacaftor (VX-809)
and acutely added ivacaftor restored the function of native
F508del-CFTR protein in primary cultures of CF human
bronchial epithelia (HBE) obtained from F508del homozy-
gous CF patients to ~35% of wild-type CFTR function in
normal HBE. Because this level of functional correction is
predicted to translate into clinical benefit based on studies ofhttp://dx.doi.org/10.1016/j.jcf.2014.10.001
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Cl− channel function [7], these in vitro studies provided the
rationale for a corrector–potentiator combination therapy
that was recently tested in phase 2 and phase 3 clinical trials
with F508del homzygous CF patients [8]1. In these trials,
chronic co-administration of lumacaftor and ivacaftor showed a
small, but significant improvement in lung function (ΔFEV1%
predicted = 2.6 to 4.0%), improved disease stability (pulmonary
exacerbations fell by 30 to 39%) and reduced modestly sweat Cl−
concentration (~–10 mmol/l) 1.
Two recent publications by Cholon et al. [9] and Veit
et al. [10] in Science Translational Medicine unexpectedly
demonstrate that chronic co-administration of lumacaftor and
ivacaftor reduces, rather than enhances, functional rescue of
F508del-CFTR in a dose-dependent fashion, a finding that
may explain the recent clinical trial data [8] 1. Cholon et al. [9]
treated primary F508del-CFTR HBE cultures for 48 h with
lumacaftor and ivacaftor to mimic clinical administration of
corrector–potentiator combination therapy. Using functional
assays, the authors demonstrated that chronic, but not acute,
treatment with ivacaftor abrogates pharmacological correction
of F508del-CFTR by lumacaftor and the investigational corrector
VX-661. Significantly, chronic ivacaftor treatment also reduced
UTP-stimulated transepithelial Cl− secretion (mediated by Ca2+--
activated Cl− channels that serve as a “back-up” secretory pathway
in CF airways [2]), suggesting potential off-target effects. Cholon
et al. [9], but not Veit et al. [10], found that chronic ivacaftor
treatment decreased wild-type CFTR function in non-CF HBE
cultures, a finding potentially relevant when considering ivacaftor
for pharmacotherapy of acquired CFTR dysfunction in cigarette
smoke-induced chronic obstructive lung disease (COPD) [11]. To
explain their functional data, Cholon et al. [9] demonstrate
that chronic administration of ivacaftor decreases the protein
stability of corrected F508del-CFTR, but not G551D-CFTR.
Finally, using computer modeling, the authors argue that
ivacaftor destabilizes CFTR structure. Like oil on a rusty gate,ll rights reserved.
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rigid structure. However, this effect is devastating for the
delicate structure of F508del-CFTR.
Using a complementary experimental approach, Veit et al.
[10] confirm that chronic ivacaftor administration impairs protein
stability, thus reducing lumacaftor- and VX-661-corrected
F508del-CFTR function at the apical membrane. Of note, the
authors extended their studies to a series of investigational
potentiator compounds. Similar to ivacaftor, chronic treatment
with most of the potentiators tested reduced the correction
efficacy of lumacaftor and VX-661. However, Veit et al. [10]
identified one potentiator (P5 (ΔF508act−02), which potentiates
F508del-, but not G551D-CFTR [12]) that did not jeopardize
F508del-CFTR stability. This result argues that functional en-
hancement of rescued F508del-CFTR might be achievable with
potentiators other than ivacaftor. Interestingly, the authors' data
argue that such potentiators should lock together the two
nucleotide-binding domains of CFTR. Finally, the authors
show that the untoward effects of chronic ivacaftor treatment
are not unique to F508del-CFTR, but also affect some rare CFTR
processing mutations.
Collectively, the studies by Cholon et al. [9] and Veit et al.
[10] provide compelling evidence that chronic treatment with
ivacaftor causes destabilization of F508del-CFTR resulting in
reduced corrector efficacy of lumacaftor in CF cell models and
primary HBE cultures. Although limited to in vitro studies in
model systems, these results may explain the modest effects on
sweat Cl− concentration and lung function observed in recent
lumacaftor–ivacaftor combination therapy trials in F508del
homozygous CF patients [8] 1. Thus, the data have important
implications for the future development of mutation-specific
drug therapies. First, these and other [13] studies demonstrate
that chronic treatment with CFTR potentiators may have
unexpected effects that cannot be predicted from acute
responses observed in in vitro studies. Hence, the effect of
long-term potentiator treatment needs to be assessed more
carefully in both preclinical models and clinical trials. Second,
the findings suggest that changes in the dosing regimen (i.e.
achieving lower and probably more pulsatile ivacaftor concen-
trations in target tissues) may be required to improve the
efficacy of lumacaftor–ivacaftor combination therapy. Third,
the data raise hope that it will be possible to develop innovative
potentiators that optimize the functional rescue of F508del-CFTR
in combination with corrector compounds without interfering with
CFTR stability.
Although at first sight appearing as a setback, the
unexpected insights provided by the studies by Cholon et al.
[9] and Veit et al. [10] will in the long term assist the
development of more effective mutation-specific drug thera-
pies. Because the relationship between the accepted licensing
endpoint FEV1 and mutant CFTR function is inherently
complex and not well understood, we propose that future
clinical trials place greater emphasis on quantitative assessment
of CFTR mutant function in vivo, using emerging assays such
as β-adrenergic sweat secretion and bioelectric measurements
in rectal biopsies [14–16]. We believe that such an approach
will detect potential pitfalls earlier and gain better insight intothe variability of treatment responses, thus accelerating the
complex and time consuming development of alternative
dosing regimen and/or new corrector–potentiator combination
therapies for CF.References
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